Maker of promising Alzheimer’s drug Leqembi expects full FDA approval this summer, expanded Medicare coverage - Earth News Report
In this articleBIIBESALY4523.T-JPFollow your favorite stocksCREATE FREE ACCOUNT Tek Image/science Photo Library | Science Photo Library | Getty Images Japanese drugmaker Eisai expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey new antibody under Medicare. U.S. CEO Ivan Cheung said the FDA,
